However, it remains unknown whether pharmacological inhibition of NHE1 potentiates TMZ-induced cytotoxicity and modifies the immunosuppressive tumor microenvironment to enhance the antitumor immunity in preclinical GBM animal models. This evidence concerns the gene SLC9A1 and neoplasm.